Amikacin (formerly called BB-K8) is a semisynthetic derivative of kanamycin A, and since the 1-amino group of the deoxystreptamine ring is acylated with a 2-hydroxy-4-aminobutyric acid (HABA) side chain, it is also called 1-N-HABA-kanamycin A (Fig. 1) .
Amikacin may be modified, in principle, at the same sites and by the same enzymes as is kanamycin A. However, due to the presence of the HABA substituent in general the 3'-hydroxyl and the 3-amino groups are not easily accessible for modification (13) , whereas the 2"-hydroxyl group may be phosphorylated (9) but not adenylylated (1) (Fig. 1) . Aminoglycoside phosphotransferase [APH(3')-III] (5) and APH(3')-IV, present in some Staphylococcus aureus and Staphylococcus epidermidis strains (8) , have been reported to modify amikacin, even though these strains were susceptible to amikacin.
We therefore questioned whether bacteria can acquire an APH(3')-mediated resistance to amikacin. To examine this, we adapted an Escherichia coli strain susceptible to amikacin, but containing an APH(3')-II, to high concentrations of amikacin, and this report is a study of the acquired resistance.
MATERLALS AND METHODS
Bacterial strains. E. coli W677 HJR66 was obtained from J. Dankert , Laboratory of Medical Microbiology, University Hospital Groningen, Groningen, The Netherlands. This strain was isolated as a mutant resistant to high levels of gentamicin after E. coli W677 JR66 was plated on a tryptic soy agar plate containing 200 jtg of gentamicin per ml (14) . Both strains produce the same three aminoglycoside-modifying enzymes: APH(3')-II; ANT(2"), an aminoglycoside adenylylating enzyme (1) ; and APH(3"), a streptomycin-modifying enzyme (11) . For E. coli W677 HJR66, we confirmed the presence of these enzymes on the basis of enzymatic activity patterns against several aminoglycosides in the assay described below. An ANT(2")-negative strain, E. coli W677 HJR66-A, was isolated by us after replica plating of E. coli W677 HJR66 on plates containing gentamicin (20 ,Lg/ml) and kanamycin (50 ,tg/ml), respectively.
The E. coli K-12 strain used in conjugation experiments as a recipient strain is resistant to nalidixic acid (minimal inhibitory concentration: MIC: 256 Lg/ml) and rifampin (MIC > 512 ,ug/ml).
E. coli K-12 GB66, a transconjugant of E. coli W677 HJR66-A and E. coli K-12 (Nal' Rifr), was selected on kanamycin. All 10 ,ug), kanamycin or neomycin (both at 30 ILg), or spectinomycin (20 jg).
Conjugative plasmid transfer. Conjugative plasmid transfer experiments were performed as described previously (2) . After conjugation, the diluted washed suspensions were plated on brain heart infusion agar plates containing rifampin (100 ,tg/ml), nalidixic acid (80 jg/ml), and kanamycin (50 ug/ml) or amikacin (ranging from 2 to 128 ,ug/ml) as selective agents.
Development of amikacin-resistant E. coli E. coli W677 HJR66, E. coli W677 HJR66-A, and E. coli K-12-GB66 were less susceptible to amikacin than was E. coli K-12 and contained APH(3')-II activity. E. coli W677-HJR66-A and E. coli K-12-GB66 were adapted to amikacin concentrations in several steps. The cells were adapted to and maintained at the concentrations of 0, 10, 20, 30, 40, 50, 100, 250, 500, and 5,000 ,ug of amikacin per ml, respectively.
Cell-free sonicates and osmotic shock extracts. Cell-free sonicates were prepared as described previously (2) . Cell-free osmotic shock extracts were prepared by the double osmotic shock procedure of Dankert and Woltjes (6) .
Assay of aminoglycoside-modifying activity. Enzymatic modification of an aminoglycoside was as- VOL. 20, 1981 on October 16, 2017 by guest http://aac.asm.org/ Downloaded from sayed by adsorption of the radioactive, modified aminoglycoside onto phosphocellulose paper (1 by 1 cm; Whatman P-81). The specific activity is given in nanomoles of aminoglycoside modified per milligram of protein per minute at the assay temperature (30°C). The assays of adenylylating, acetylating, and phosphorylating enzymes (reaction time, 30 min) were essentially as described by Haas and Dowding (7). The reaction mixture for APH(3') assays contained 10 01 of enzyme solution, 10 t,l of tris(hydroxymethyl)aminomethane (Tris) buffer (pH 7.5) prepared as described by Haas and Dowding (7), 10,ul of 0.5 mM [y-32P]adenosine 5'-triphosphate solution (50,uCi/ml), and 5 1.l of 1 mM aminoglycoside solution; the aminoglycoside concentration was increased 2.5-and 25-fold to study the effect of the substrate concentration. The enzyme solution was diluted until the enzymatic activities had reached a range at which these activities (expressed in counts per minute) were proportional to the dilution of the enzyme.
Protein determination. Protein determination was by the Folin-Ciocalteu method of Lowry et al. (10) , with bovine serum albumin as standard.
Affinity chromatography. APH(3')-II was partly purified by means of a Sepharose-4B affinity chromatography column (length, 25 cm; bed volume, 20 ml), to which kanamycin or tobramycin (as a ligand for the enzyme) had been coupled in accordance with the instructions of Pharmacia. The loaded column was washed with 0.1 M Tris-hydrochloride (pH 8.0) until no further ultraviolet-absorbing material was eluted from the column when it was screened at 280 and 260 nm. In this wash procedure, APH(3") was removed from the column. Elution was carried out discontinuously with 0, 0.4, 0.6, 0.8, 1.0, and 1.5 M NH4Cl, respectively, in 0.1 M Tris-hydrochloride (pH 8.0). The APH(3') activity was eluted, starting with 0.4 M NH4Cl (for the tobramycin column) or 0.6 M NH4Cl (for the kanamycin column). For some purposes, fractions with APH(3') activity were pooled and centrifuged for 18 h at 100,000 x g. The supernatants always contained about 95 to 99% of the APH(3') activity, and the pellet fraction was discarded.
Phosphorylation of amikacin. To evaluate amikacin activity after modification, amikacin was modified by APH(3')-II in vitro, and afterwards, 3'-O-phosphoryl-amikacin was purified and tested for antimicrobial activity. The cell-free sonicate of cells harvested from a 2-liter culture of E. coli K-12 GB66 (adapted to and grown in the presence of 50 ,Lg of amikacin per ml) was applied to a kanamycin affinity column. The APH(3') activity, which was free of APH(3"), eluted at 0.6 M NH4Cl and was mixed with 1 g of amikacin and 2 g of adenosine 5'-triphosphate (disodium salt), filter sterilized, and incubated at 37°C for 1 week. The progress of the enzymatic reaction was checked with Silica Gel thin-layer chromatography (TLC plates; Merck, art. 5721) as described by Umezawa and Kondo (15) , with butanol-ethanol-chloroform-28% ammonia (4:5:2:8) as the developing system. Detection was performed with 0.1% ninhydrin in acetone; the Rf values for amikacin and 3'-O-phosphoryl-amikacin were 0.08 and 0.14, respectively. A part of the reaction mixture was applied to a cation-exchange column (BioRex 70; 100 to 200 mesh) and eluted discontinuously with 0, 0.5, 1.5, 2.0, 2.5, 3.0, and 3.5 M NaCl in 0.05 M sodium potassium phosphate buffer (pH 7.0). The eluted fractions were checked both by a spot test for the presence of (modified) aminoglycoside and by thin-layer chromatography. 3'-O-phosphoryl-amikacin was eluted with 1.5 M NaCl in 0.05 M phosphate buffer, and amikacin was eluted with 3.0 M NaCl.
Plasmid isolation and electrophoresis. Cells were cultured in brain heart infusion broth, supplemented, if necessary, with 50 t.g of amikacin per ml, at 37°C in an environmental incubator (200 rpm) up to an absorbance of 0.7 at 600 nm (exponential phase of growth). Plasmid isolation and agarose gel electrophoresis were performed essentially as described by Casse et al. (4) .
Amino acid incorporation experiments. The amino acid incorporation experiments were carried out in the Laboratory of Protein-Biosynthesis Study, Department of Biochemistry, University of Leiden, The Netherlands. Three liters of cells were cultured at 37°C to an absorbance of 0.7 to 0.8 at 600 nm in brain heart infusion broth, harvested by centrifugation, and washed twice with physiological saline. All manipulations were performed at 0 to 4°C. Ribosomes 
RESULTS
Levels of amikacin resistance acquired in adaptation. The MIC of amikacin for E. coli K-12 GB66 is 2 ,tg/ml; the variant adapted to 10 ,ug/ml showed an MIC of 128 ,ug/ml (Table 2 ).
This MIC remained constant during adaptation to up to 100 ,g of amikacin per ml. The variants grown in 250, 500, or 5,000 ,ig of amikacin per ml had higher amikacin resistance levels. In all variants, amikacin resistance was coupled with resistance to both kanamycin and neomycin. After three passages in antibiotic-free medium, the MICs of amikacin were only lowered twofold or were identical; thus, this amikacin resistance appears to have a stable character.
The colony numbers of the variants adapted to up to 250 ,ug of amikacin per ml decreased at increasing amikacin concentrations in the MIC determinations, but for the variants adapted to 500 and 5,000 ,g of amikacin per ml, only the size of the colonies decreased (from small colonies to pinpoint colonies at the last concentration before the MIC). This corresponds with the differences in doubling time (as calculated from turbidity) of the variants in antibiotic-free medium: for the variants adapted to up to 250 ,ug/ ml, the doubling time was 30 to 35 min, and for the variants adapted to 500 and 5,000 ,ug/ml, the doubling time was 60 and 85 min, respectively.
Identification of the APH(3') activity.
Both the cell-free osmotic shock extracts and the cell-free sonicates of E. coli W677 HJR66 (3) . We confirmed this finding, but we also observed inhibition of the phosphorylation of amikacin. These results might imply the presence of two types of APH(3') enzymes, and this was further studied by affinity chromatography with covalently bound kanamycin and tobramycin. Cell-free osmotic shock extracts and sonicates of E. coli K-12 GB66 variants, which had been adapted to 0, 50, 500, or 5,000 ,ug of amikacin per ml, and of E. coli W677 HJR66 and W677 HJR66-A were applied to the affinity columns and eluted with discontinuous salt gradients. All eluted fractions were tested for phosphorylating activity towards kanamycin, neomycin, and amikacin, and identical substrate profiles were observed. In addition, the substrate and tobramycin inhibition profiles were identical to the profiles of the enzyme before affinity chromatography. No indication of the presence of more than one type of APH(3')-II enzyme was found. The increase of amikacin resistance therefore could not be explained by a differential increase of a second type of APH(3') enzyme.
3'-hydroxyl modification of amikacin by APH(3')-II. APH(3')-II [free of APH(3")] was used to prepare phosphorylated amikacin from amikacin and adenosine 5'-triphosphate. After the enzymatic reaction was stopped, a small amount of amikacin was still present. A minor part of the reaction mixture was purified by cation-exchange chromatography, and a disk with 200 ,ug of purified 3'-Q-phosphoryl-amikacin did not show antibacterial activity towards E. coli K-12. The antibacterial activity of the nonpurified major part of the reaction mixture was found to be 32-fold lower than that of amikacin. This implies that about 3 to 5% amikacin activity was present in the reaction mixture which agrees with the chromatographic observation. These results showed that amikacin is inactivated by 3'-OH phosphorylation.
APH(3')-II levels after adaptation to amikacin. Because of the inactivation of amikacin by unchanged APH(3')-II and its presence in the amikacin-resistant variants, the APH(3')-II level was studied. In the adaptation of E. coli K-12 GB66 and E. coli W677 HJR66-A from 0 to 10 jig of amikacin per ml, the level of APH(3')-II increased 5-to 10-fold (Table 3 ). This was also true for APH(3"). The variants adapted to concentrations of >10 ,g of amikacin per ml all had APH(3')-II levels similar to the level of the variant adapted to 10 ,ug of amikacin per ml.
Copy number and molecular weight of plasmids. An APH(3')-II increase (Table 3) VOL. 20, 1981 on October 16, 2017 by guest http://aac.asm.org/ Downloaded from might be caused by an increase of either the number of APH(3')-II genes on the same plasmid or the plasmid copy number (gene dosage). On agarose gels (Fig. 2) , an identical plasmid band (pBN66) is shown for both E. coli K-12-GB66 and the variant adapted to 50 jig of amikacin per ml, regardless of whether the latter was subsequently cultured in the presence or absence of amikacin. A strong difference was observed in the amount of deoxyribonucleic acid in the plasmid bands of the adapted and nonadapted E. coli. In experiments with diluted plasmid DNA preparations, no evidence could be GB66 not adapted to amikacin (A) and adapted to 50 pg of amikacin per ml but grown in the absence of amikacin (B) and in the presence of50 jg ofamikacin per ml (C). The upper band represents the plasmid DNA; the lower band represents chromosomal DNA. The plasmid isolation procedure was performed on the same quantity of exponentially growing cells.
obtained for an increase in the molecular weight of the plasmid. Also, additional small plasmids were not detected. Thus, an increase of APH(3')-II coincided with an increase in plasmid copy number. Amikacin-adapted cells did not show changes in MIC after serial transfer in antibioticfree medium (Table 2) , nor did the plasmid copy number of these cells show any sign of decrease.
In contrast to the masses of the plasmids reported to be present in E coli W677 JR66 (57 and 40 to 57 megadaltons [12] ), the mass of this plasmid (pBN66) was estimated to be 110 megadaltons.
Basis of the enhanced enzyme and plasmid levels. The constant and enhanced enzyme levels and the increased plasmid copy number are probably due to a mutation which affects regulation of the plasmid copy number. To clarify this phenomenon, we studied the transferability of this property with an amikacin-resistant variant of E. coli W677 HJR66-A (Nal' Rif'), which had the same properties as did the amikacin-resistant variants of E. coli K-12 GB66 with regard to susceptibilities to antibiotics, except for the susceptibilities to nalidixic acid and rifampin. This strain served as the donor, with E. coli K-12 (Nalr, Rif) as the recipient. Selection of the APH(3')-II-containing transconjugants was performed on plates containing 2 to 128 ,ug of amikacin per ml. The MICs of amikacin for the colonies from the selective plates with low amikacin concentrations (up to 8 ,ug/ml) were always low (2 to 4 ytg/ml); those for the sparse colonies from selective plates with high amikacin concentrations (16 to 128 .tg/ml) were 264 ,ug/ml. The occurrence of these latter colonies was 106-fold less frequent than that of the first colonies. The low frequency of amikacin resistance in the transconjugant population strengthened the suggestion of a plasmid copy number mutation and also showed that this mutation is not transferable.
Evidence for additional resistance mechanisms other than APH(3')-Hl in the variants adapted to 500 and 5,000 ,ug of amikacin per ml. The E. coli K-12 GB66 variants adapted to 500 and 5,000 ,u.g of amikacin per ml proved to have APH(3')-II levels similar to those found for the variants adapted to 10 to 100 jig of amikacin per ml. This suggests that one or more additional resistance mechanisms must be present. One of these mechanisms might be a ribosomal mutation. The variant adapted to 500 ,tg/ ml was studied for such a mutation. Experiments on misreading in protein synthesis due to amikacin were not performed, but amino acid incorporation in vitro was studied.
In experiments with MS-2 ribonucleic acid as messenger ribonucleic acid and ribosomes from either E. coli K-12 GB66 or the variant adapted to 50 jig of amikacin per ml, amino acid incorporation was strongly inhibited (95%) by amikacin at 500 ug/ml, whereas with ribosomes of the variant adapted to 500 ,g/ml, incorporation was inhibited by only 60%. DISCUSSION E. coli K-12 GB66 (and its parental strains, E. coli W677 HJR66 and HJR66-A) showed a decreased susceptibility to amikacin as compared with the susceptibility of the plasmid-free E.
coli K-12. This decreased susceptibility was found to be transferable and was coupled with resistance to kanamycin, neomycin, and streptomycin. The structural similarity of amikacin with kanamycin made APH(3')-II suspect as the cause of this decreased susceptibility.
The substrate profiles of the APH(3') activity of E. coli W677 HJR66, W677 HJR66-A, and K-12-GB66 were identical. Since tobramycin inhibited the phosphorylation of kanamycin and amikacin but not that of neomycin, the question arose as to whether we were dealing with one or two APH(3') enzymes. The finding that all of the APH(3') activity fractions eluted from the affinity columns showed the same substrate and tobramycin inhibition profile argues for the presence of one enzyme.
For enzyme-mediated resistance in gram-negative bacteria, it is necessary that (i) the antibiotic is modified on the basis of the presence of the required modifiable group; (ii) the antibiotic becomes inactive after modification; and (iii) the modifying activity present in the periplasmic space of the bacterium is sufficient to inactivate a high enough percentage of the penetrating antibiotic molecules that the amount of nonmodified antibiotic transported into the cell cannot inhibit bacterial growth completely. Since amikacin was inactivated by APH(3')-II-mediated phosphorylation, and since amikacin modification by APH(3')-II occurred only at a low rate as compared with neomycin, the lack of correlation between modification and inactivation of amikacin in the nonadapted E. coli K-12 GB66 must be due to a low level of amikacinmodifying activity. During the adaptation, variants with enhanced APH(3') levels arose. In the cells adapted to 10 to 5,000 ,ug of amikacin per ml, the increase in APH(3')-II level was 5-to 10-fold. These data strongly suggest that it is not the substrate profile (i.e., the relative modification rates) but rather the absolute enzyme activity (enzyme level) that is important for resistance.
There are two strong arguments for the contention that the increase in APH(3')-II is due to increased plasmid copy number. First, there is a correlation between the increase of APH(3')-II and the increased amount of DNA in the plasmid band upon agarose gel electrophoresis. Second, an absolute correlation between the APH(3')-II and the APH(3") level has been found. Both enzymes are coded for by genes which are located on a single plasmid.
This increase was found to be irreversible after four passages in antibiotic-free medium and is therefore ascribed to a mutation which affects the plasmid copy number. As far as we know, aminoglycoside resistance based on increase in copy number of plasmids has never been reported before. In view of the negative results of attempts to transfer this property, it is probable that the mutation is located on the bacterial chromosome and not on the plasmid.
In E. coli W677 JR66, APH(3')-II and APH(3") are coded for by each of two plasmids, the self-transmissible plasmid JR-66.a (equivalent to JR-67) and the nontransmissible plasmid JR-66.b; the masses of these plasmids are 57 and 40 to 57 megadaltons, respectively (12) . In E. coli W677 HJR66-A and E. coli K-12 GB66, these two enzymes are coded for by a plasmid (pBN66) with a mass of 110 megadaltons. The possibility of a dimeric structure of JR-66.a is not excluded and is under study. Perlin and Lerner (12) have studied APH(3')-mediated amikacin resistance in E. coli W677 JR66 (the origin of E. coli W677 H7R66; see Table 1 ) and some transconjugants; they explained this resistance on the basis of a changed enzyme activity profile. Yet their results (12) still agree with ours in many aspects: (i) the amikacin resistance is due to a mutation, irreversible and not transferable, which data strongly argue for a chromosomal location of the mutation; (ii) amikacin-resistant transconjugants were only selected by use of amikacin and not with kanamycin; (iii) for strains with low amikacin MICs, low APH(3') levels were found, and high levels were found only for strains with high MICs; (iv) comparison of the ratios of phosphotransferase activities against kanamycin and amikacin in cell-free sonicates of the amikacin- 
